- Home
- CGTX
as 12-20-2024 4:00pm EST
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | PITTSBURGH |
| Market Cap: | 16.1M | IPO Year: | 2021 |
| Target Price: | $8.30 | AVG Volume (30 days): | 20.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.95 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.34 - $2.95 | Next Earning Date: | 11-13-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Cognition Therapeutics Inc. News
CGTX Breaking Stock News: Dive into CGTX Ticker-Specific Updates for Smart Investing
TipRanks
2 days ago
B. Riley upgrades Cognition Therapeutics to Buy on Lewy bodies data
MT Newswires
3 days ago
B. Riley Upgrades Cognition Therapeutics to Buy From Neutral, Lifts PT to $1.50 From $1
TipRanks
3 days ago
Cognition Therapeutics announces results in Phase 2 study of CT1812
MT Newswires
4 days ago
Cognition Therapeutics Says Study of Drug to Treat Lewy Body Dementia Meets Primary Endpoint; Shares Jump
GlobeNewswire
4 days ago
Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies
Simply Wall St.
9 days ago
We're A Little Worried About Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate
Zacks
24 days ago
Cognition Therapeutics (CGTX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
TipRanks
a month ago
Cognition Therapeutics provided an update on Phase 2 ‘SHINE’ study analysis
Compare CGTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CGTX Cognition Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.